Berenberg Bank Analysts Give Stratec Biomedical (SBS) a €59.00 Price Target

Berenberg Bank set a €59.00 ($70.24) price target on Stratec Biomedical (ETR:SBS) in a report issued on Thursday. The firm currently has a neutral rating on the stock.

Several other equities analysts also recently commented on the stock. Kepler Capital Markets set a €70.00 ($83.33) price target on shares of Stratec Biomedical and gave the company a buy rating in a report on Friday, October 27th. Warburg Research set a €62.00 ($73.81) price target on shares of Stratec Biomedical and gave the company a buy rating in a report on Thursday, October 26th. Deutsche Bank set a €56.00 ($66.67) price target on shares of Stratec Biomedical and gave the company a neutral rating in a report on Tuesday, October 24th. Finally, Oddo Bhf set a €58.00 ($69.05) price target on shares of Stratec Biomedical and gave the company a neutral rating in a report on Monday, October 23rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Stratec Biomedical has an average rating of Hold and a consensus target price of €60.50 ($72.02).

Stratec Biomedical (ETR SBS) opened at €67.74 ($80.64) on Thursday. Stratec Biomedical has a fifty-two week low of €41.30 ($49.17) and a fifty-two week high of €69.85 ($83.15).

COPYRIGHT VIOLATION NOTICE: “Berenberg Bank Analysts Give Stratec Biomedical (SBS) a €59.00 Price Target” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/10/berenberg-bank-analysts-give-stratec-biomedical-sbs-a-59-00-price-target.html.

Stratec Biomedical Company Profile

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit